Cargando…

Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)

Purpose. To characterize the economic and quality of life burden of diabetic macular edema (DME) in Canadian patients. Patients and Methods. 145 patients with DME were followed for 6 months with monthly telephone interviews and medical chart reviews at months 0, 3, and 6. Visual acuity in the worst-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonder, John R., Walker, Valery M., Barbeau, Martin, Zaour, Nancy, Zachau, Bryan H., Hartje, James R., Li, Ruihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984851/
https://www.ncbi.nlm.nih.gov/pubmed/24795818
http://dx.doi.org/10.1155/2014/939315
_version_ 1782311504402448384
author Gonder, John R.
Walker, Valery M.
Barbeau, Martin
Zaour, Nancy
Zachau, Bryan H.
Hartje, James R.
Li, Ruihong
author_facet Gonder, John R.
Walker, Valery M.
Barbeau, Martin
Zaour, Nancy
Zachau, Bryan H.
Hartje, James R.
Li, Ruihong
author_sort Gonder, John R.
collection PubMed
description Purpose. To characterize the economic and quality of life burden of diabetic macular edema (DME) in Canadian patients. Patients and Methods. 145 patients with DME were followed for 6 months with monthly telephone interviews and medical chart reviews at months 0, 3, and 6. Visual acuity in the worst-seeing eye was assessed at months 0 and 6. DME-related healthcare costs were determined over 6 months, and vision-related (National Eye Institute Visual Functioning Questionnaire) and generic (EQ-5D) quality of life was assessed at months 0, 3, and 6. Results. Mean age of patients was 63.7 years: 52% were male and 72% had bilateral DME. At baseline, visual acuity was categorized as normal/mild loss for 63.4% of patients, moderate loss for 10.4%, and severe loss/nearly blind for 26.2%. Mean 6-month DME-related costs/patient were as follows: all patients (n = 135), $2,092; normal/mild loss (n = 88), $1,776; moderate loss (n = 13), $1,845; and severe loss/nearly blind (n = 34), $3,007. Composite scores for vision-related quality of life declined with increasing visual acuity loss; generic quality of life scores were highest for moderate loss and lowest for severe loss/nearly blind. Conclusions. DME-related costs in the Canadian healthcare system are substantial. Costs increased and vision-related quality of life declined with increasing visual acuity severity.
format Online
Article
Text
id pubmed-3984851
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39848512014-05-04 Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY) Gonder, John R. Walker, Valery M. Barbeau, Martin Zaour, Nancy Zachau, Bryan H. Hartje, James R. Li, Ruihong J Ophthalmol Research Article Purpose. To characterize the economic and quality of life burden of diabetic macular edema (DME) in Canadian patients. Patients and Methods. 145 patients with DME were followed for 6 months with monthly telephone interviews and medical chart reviews at months 0, 3, and 6. Visual acuity in the worst-seeing eye was assessed at months 0 and 6. DME-related healthcare costs were determined over 6 months, and vision-related (National Eye Institute Visual Functioning Questionnaire) and generic (EQ-5D) quality of life was assessed at months 0, 3, and 6. Results. Mean age of patients was 63.7 years: 52% were male and 72% had bilateral DME. At baseline, visual acuity was categorized as normal/mild loss for 63.4% of patients, moderate loss for 10.4%, and severe loss/nearly blind for 26.2%. Mean 6-month DME-related costs/patient were as follows: all patients (n = 135), $2,092; normal/mild loss (n = 88), $1,776; moderate loss (n = 13), $1,845; and severe loss/nearly blind (n = 34), $3,007. Composite scores for vision-related quality of life declined with increasing visual acuity loss; generic quality of life scores were highest for moderate loss and lowest for severe loss/nearly blind. Conclusions. DME-related costs in the Canadian healthcare system are substantial. Costs increased and vision-related quality of life declined with increasing visual acuity severity. Hindawi Publishing Corporation 2014 2014-03-26 /pmc/articles/PMC3984851/ /pubmed/24795818 http://dx.doi.org/10.1155/2014/939315 Text en Copyright © 2014 John R. Gonder et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gonder, John R.
Walker, Valery M.
Barbeau, Martin
Zaour, Nancy
Zachau, Bryan H.
Hartje, James R.
Li, Ruihong
Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)
title Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)
title_full Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)
title_fullStr Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)
title_full_unstemmed Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)
title_short Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)
title_sort costs and quality of life in diabetic macular edema: canadian burden of diabetic macular edema observational study (c-reality)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984851/
https://www.ncbi.nlm.nih.gov/pubmed/24795818
http://dx.doi.org/10.1155/2014/939315
work_keys_str_mv AT gonderjohnr costsandqualityoflifeindiabeticmacularedemacanadianburdenofdiabeticmacularedemaobservationalstudycreality
AT walkervalerym costsandqualityoflifeindiabeticmacularedemacanadianburdenofdiabeticmacularedemaobservationalstudycreality
AT barbeaumartin costsandqualityoflifeindiabeticmacularedemacanadianburdenofdiabeticmacularedemaobservationalstudycreality
AT zaournancy costsandqualityoflifeindiabeticmacularedemacanadianburdenofdiabeticmacularedemaobservationalstudycreality
AT zachaubryanh costsandqualityoflifeindiabeticmacularedemacanadianburdenofdiabeticmacularedemaobservationalstudycreality
AT hartjejamesr costsandqualityoflifeindiabeticmacularedemacanadianburdenofdiabeticmacularedemaobservationalstudycreality
AT liruihong costsandqualityoflifeindiabeticmacularedemacanadianburdenofdiabeticmacularedemaobservationalstudycreality